2017: the year in pharmacy Subscription
Against a backdrop of political inertia caused by a surprise general election and protracted Brexit negotiations, pharmacy has been grappling with some major issues of its own, including supervision of medicines’ supply, professional revalidation and decriminalisation of dispensing errors (see 2017: ...
The over-the-counter medicines market grew by 2.3% during 2016 to reach £2.62bn.
A brief history of ibuprofen Subscription
This timeline traces the history of popular anti-inflammatory drug ibuprofen, from its invention in the 1960s to its association with cardiac side effects.
A decade of community pharmacy funding in England Subscription
Community pharmacies in England dispense 174 million more prescription items annually than in 2010, a figure that is predicted to rise further. Despite this, total funding for the community pharmacy contract is heading back towards 2010 levels.
A decade of smoking cessation in Europe Subscription
The continent with the worst smoking habit is gradually giving it up. A range of anti-smoking policies and new cessation products has led to reduced rates of smoking in most countries, which will eventually impact on smoking-related deaths.
A history of aspirin Subscription
Aspirin was one of the first drugs to come into common usage and it still one of the most researched drugs in the world, with an estimated 700 to 1,000 clinical trials conducted each year.
A history of HIV survival in the UK Subscription
Treatment for HIV has radically improved since the beginning of the epidemic in 1981. HIV-infected people in the UK are now surviving for decades, rather than months or years.
A quick guide to medical cannabis Subscription
With medical cannabis now legal in 44 countries around the world, and the UK likely to follow suit, here is what pharmacists need to know.
A visual guide to the Ebola virus epidemic Subscription
As the 2014 Ebola virus epidemic continues to escalate, we chart the latest epidemiological data alongside an insight into the pathology of Ebola virus disease and the biological processes being targeted by drug and vaccine developers.
Atopic dermatitis: emerging and current treatments Subscription
Atopic dermatitis affects up to 30% of children and 10% of adults, and is common in both developed and developing countries. Two new medicines on the brink of entering the market — dupilumab, a biologic for severe disease, and crisaborole, a topical small molecule drug for milder disease — could herald a new era in the management of this condition, which has seen no major changes to the way it has been treated for over 15 years.